Related Experiment Video
Updated: Jun 15, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
Published on: April 21, 2022
[Recombinant human DNase in conditions other than cystic fibrosis]
1Paediatrisk Klinik 2, 4072, Rigshospitalet, DK-2100 København Ø, Denmark. kimk@dadlnet.dk
Abstract:
Recombinant human DNase (rhDNase) reduces viscosity of sputum. Effect has been documented in cystic fibrosis and postoperatively in paediatric heart disease. Single dose treatment with rhDNase in paediatric asthma has no effect. In respiratory syncytial virus infection, treatment with rhDNase may be associated with increased need for supplemental oxygen. In adults with idiopathic bronchiectasis, treatment with rhDNase leads to more pulmonary exacerbations and a greater decline in pulmonary function tests. There are no controlled studies on rhDNase in primary ciliary dyskinesia or atelectasis.
More Related Videos
15:12Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
Published on: May 10, 2014
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Recombinant DNA
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...